Veeraraghavan Gayathri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Veeraraghavan Gayathri has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Arghadip Das
Centre for Toxicology and Developmental Research (CEFTE), Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu 600116, India
2 shared publications - Emmanuel Bhaskar
Department of General Medicine, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, India 600116
2 shared publications - Parthasarathy Mohanalakshmi
Department of Biochemistry, Sri Muthukumaran Medical College Hospital and Research Institute, Kunrathur Road, Chikkarayapuram, Chennai, India 600069
2 shared publications - Priyadharshini Palani
Centre for Toxicology and Developmental Research (CEFTE), Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu 600116, India; Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu 600116, India
2 shared publications - Sowmiya Thiagarajan
Department of Biochemistry, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, India 600116
2 shared publications Arghadip Das
Centre for Toxicology and Developmental Research (CEFTE), Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu 600116, India
1 shared publication
Latest Publications
- Open Access
- 9 June 2026
- Published by SAGE Publications in Annals of Neurosciences
A Novel Approach of Development of Robust Animal Model for Autism Spectrum Disorder
Background: Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental disorder. Numerous environmental risk factors have been implicated in the development of ASD in human cases, suggesting that multiple aetiological agents may contribute to developing an ASD rodent model. In this study, we have investigated the pathobiological processes and outcomes in a novel rat model of ASD that incorporates clinically relevant prenatal and perinatal insults. Specifically, a gamma-aminobutyric acid modulator, valproic acid (VPA), used for perinatal insults, and postnatal hypoxia was combined to understand the critical stages of brain development in rat pups and to explore potential causal mechanisms underlying ASD. Purpose: To develop the robust animal model for ASD using VPA and hypoxia as causative agents in combination to test other efficacious medicines for ASD in future. Method: A total of 16 female and 4 male Wistar rats were selected for mating, and the delivered pups were used for the study. The pregnant female animals were divided into four groups: G1: normal control group, G2: VPA group—received a single injection of VPA intraperitoneal (i.p.) on gestational day (GD) 12.5, G3: hypoxia group, rat pups were subjected to postnatal hypoxia, G4: VPA + hypoxia group, pregnant females received VPA (i.p. on GD 12.5), followed by normal delivery, after which the pups were subjected to postnatal hypoxia. Neurodevelopmental reflex tests, neurobehavioural assessments (open field test and Morris water maze) and three-chamber social interaction tests were conducted on the rat pups. Histopathological evaluation of the pups’ brains was performed. Results: The VPA, hypoxia and combined VPA + hypoxia groups exhibited significant neurobehavioural alterations, with marked delays in neurodevelopmental reflexes compared to the normal control group. Histopathological examination of the brain revealed a reduction in Purkinje cells within the Purkinje cell layer, along with extensive neuronal degeneration. The severity of both neurobehavioural deficits and histopathological abnormalities was greatest in the combined VPA + hypoxia group compared to the other experimental groups. Conclusions: These findings suggest that the combination of prenatal VPA exposure and postnatal hypoxia, representing pre- and perinatal insults, induces ASD-like conditions in rat pups that closely resemble the clinical behaviour features and redox imbalance of human ASD. Thus, this combined model could serve as a potential animal model for ASD and could be used for screening pharmacological agents aimed at treating and managing ASD.
- 9 June 2026
- Published by SAGE Publications in Annals of Neurosciences
Open AccessA Novel Approach of Development of Robust Animal Model for Autism Spectrum Disorder
Background: Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental disorder. Numerous environmental risk factors have been implicated in the development of ASD in human cases, suggesting that multiple aetiological agents may contribute to developing an ASD rodent model. In this study, we have investigated the pathobiological processes and outcomes in a novel rat model of ASD that incorporates clinically relevant prenatal and perinatal insults. Specifically, a gamma-aminobutyric acid modulator, valproic acid (VPA), used for perinatal insults, and postnatal hypoxia was combined to understand the critical stages of brain development in rat pups and to explore potential causal mechanisms underlying ASD. Purpose: To develop the robust animal model for ASD using VPA and hypoxia as causative agents in combination to test other efficacious medicines for ASD in future. Method: A total of 16 female and 4 male Wistar rats were selected for mating, and the delivered pups were used for the study. The pregnant female animals were divided into four groups: G1: normal control group, G2: VPA group—received a single injection of VPA intraperitoneal (i.p.) on gestational day (GD) 12.5, G3: hypoxia group, rat pups were subjected to postnatal hypoxia, G4: VPA + hypoxia group, pregnant females received VPA (i.p. on GD 12.5), followed by normal delivery, after which the pups were subjected to postnatal hypoxia. Neurodevelopmental reflex tests, neurobehavioural assessments (open field test and Morris water maze) and three-chamber social interaction tests were conducted on the rat pups. Histopathological evaluation of the pups’ brains was performed. Results: The VPA, hypoxia and combined VPA + hypoxia groups exhibited significant neurobehavioural alterations, with marked delays in neurodevelopmental reflexes compared to the normal control group. Histopathological examination of the brain revealed a reduction in Purkinje cells within the Purkinje cell layer, along with extensive neuronal degeneration. The severity of both neurobehavioural deficits and histopathological abnormalities was greatest in the combined VPA + hypoxia group compared to the other experimental groups. Conclusions: These findings suggest that the combination of prenatal VPA exposure and postnatal hypoxia, representing pre- and perinatal insults, induces ASD-like conditions in rat pups that closely resemble the clinical behaviour features and redox imbalance of human ASD. Thus, this combined model could serve as a potential animal model for ASD and could be used for screening pharmacological agents aimed at treating and managing ASD.
- Open Access
- 12 February 2026
- Published by Science Publishing Corporation in International Journal of Basic and Applied Sciences
- Vol. 15 (2) , 46-54
Gut Microbiota Profiles in Common Non-Communicable Diseases- A Narrative Review
Purpose: The gastrointestinal tract in humans is composed of various microorganisms including bacteria, viruses, archaea, protozoa, and fungi. The interactions between gut and the microorganisms are crucial for the processes such as digestion, nutrient absorption, immune function, and metabolic regulation. Altered gut microbiota called dysbiosis, has been linked to the development and progression of various non-communicable diseases. This review has been aimed to address the alterations of gut microbiota in various non-communicable diseases. Methods: A thorough literature search was conducted in PubMed, Embase, Web of Science, Scopus, and Google Scholar between January 2015 and December 2024 to identify studies examining the impact of gut microbiota in metabolic diseases. The search utilized keywords such as gut microbiota, gut dysbiosis, and altered microbiota in non-communicable diseases. The studies included were full research articles and studies published in English. In this comprehensive review, we explored the complex interplay between the gut microbiota and human health, focusing on its role in common metabolic disorders such as obesity, metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, cardiovascular diseases, autoimmune diseases, mental disorders, and cancer. Studies involving animal models, and cell lines and reviews were excluded. Conclusions: The altered gut microbiota is involved in the initiation and progression of various non-communicable diseases. The dysbiosis not only aggravates the disease, but also causes refractoriness to the management of the disease. Hence, it is better to identify the causes of dysbiosis to control the harmful bacteria and to bring relief to the individuals with common con-communicable diseases.
- 12 February 2026
- Published by Science Publishing Corporation in International Journal of Basic and Applied Sciences
- Vol. 15 (2) , 46-54
Open AccessGut Microbiota Profiles in Common Non-Communicable Diseases- A Narrative Review
Purpose: The gastrointestinal tract in humans is composed of various microorganisms including bacteria, viruses, archaea, protozoa, and fungi. The interactions between gut and the microorganisms are crucial for the processes such as digestion, nutrient absorption, immune function, and metabolic regulation. Altered gut microbiota called dysbiosis, has been linked to the development and progression of various non-communicable diseases. This review has been aimed to address the alterations of gut microbiota in various non-communicable diseases. Methods: A thorough literature search was conducted in PubMed, Embase, Web of Science, Scopus, and Google Scholar between January 2015 and December 2024 to identify studies examining the impact of gut microbiota in metabolic diseases. The search utilized keywords such as gut microbiota, gut dysbiosis, and altered microbiota in non-communicable diseases. The studies included were full research articles and studies published in English. In this comprehensive review, we explored the complex interplay between the gut microbiota and human health, focusing on its role in common metabolic disorders such as obesity, metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, cardiovascular diseases, autoimmune diseases, mental disorders, and cancer. Studies involving animal models, and cell lines and reviews were excluded. Conclusions: The altered gut microbiota is involved in the initiation and progression of various non-communicable diseases. The dysbiosis not only aggravates the disease, but also causes refractoriness to the management of the disease. Hence, it is better to identify the causes of dysbiosis to control the harmful bacteria and to bring relief to the individuals with common con-communicable diseases.
- Open Access
- 11 December 2025
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
GB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology
Background: Type 2 diabetes mellitus (T2DM) remains a global health burden characterized by insulin resistance, persistent hyperglycaemia, and chronic inflammation. Although single-target therapies effectively reduce glucose levels, they seldom address oxidative stress or adipocyte dysfunction. Polyherbal formulations (PHFs) harness synergistic phytochemicals for multimodal intervention; however, many lack mechanistic transparency owing to excessive inclusion of diverse botanical bioactives, suffer from non-standardized composition, and underexplore volatile antidiabetic constituents. Confronting these challenges, we developed Gluco Balance V (GB5), a cold-percolated ethanolic extract comprising equal proportions of bio-effective parts of Asparagus racemosus , Cyperus rotundus , Tinospora cordifolia , Terminalia arjuna , and Mimosa pudica . These botanicals were selected for complementary antidiabetic, antioxidant, and adiporegulatory activities documented in preclinical and clinical settings, indicating balanced, synergistic, and safe bioactivity. Methods: GB5’s phytochemical composition was standardized using gas chromatography–mass spectrometry (GC–MS) fingerprinting. In vitro assays assessed 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide (NO) scavenging capacity, inhibition of carbohydrate-digesting enzymes (α-amylase, α-glucosidase), enzyme kinetics, and effects on glucose uptake (GU) and lipid accumulation (LA) in yeast and 3T3-L1 adipocytes. Computational network pharmacology, molecular docking, and pharmacokinetic analyses elucidated molecular targets and bioavailability. Statistical analyses employed robust dose-response modelling, analysis of variance with Dunnett’s T3 test, and t-tests with false discovery rate correction. Results: GC–MS identified 21 bioactive compounds, including phytol, fatty acids, and sterols, driving GB5’s therapeutic synergy. GB5 showed robust antioxidant activity (DPPH and NO; half-maximal inhibitory concentration (IC 50 ) 88.6 and 74.8 µg/mL) and mixed-type inhibition of α-amylase and α-glucosidase (IC 50 71.6 and 174 µg/mL). At sub-inhibitory doses, it outperformed ascorbic acid (ASA) and acarbose. In 3T3-L1 adipocytes, GB5 increased GU by 32.3% at 2.0 mg/mL, comparable to rosiglitazone, and reduced lipid accumulation by 18.6% (90% effective concentration (EC 90 ) 0.742 mg/mL). Network pharmacology and molecular docking implicated peroxisome proliferator-activated receptor gamma (PPARγ), protein tyrosine phosphatase 1B (PTP1B), cyclooxygenase-2 (COX-2), and advanced glycation end-products–receptor for advanced glycation end-products (AGE–RAGE) pathways with 9,12-octadecadienoic acid and cholestan-3-ol, 2-methylene-, (3β,5α)- as key associates. Conclusions: GB5’s multi-targeted efficacy against hyperglycaemia, oxidative stress, and adipocyte dysfunction positions it as a promising complementary therapy for T2DM, meriting further in vivo evaluation. Graphical
- 11 December 2025
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
Open AccessGB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology
Background: Type 2 diabetes mellitus (T2DM) remains a global health burden characterized by insulin resistance, persistent hyperglycaemia, and chronic inflammation. Although single-target therapies effectively reduce glucose levels, they seldom address oxidative stress or adipocyte dysfunction. Polyherbal formulations (PHFs) harness synergistic phytochemicals for multimodal intervention; however, many lack mechanistic transparency owing to excessive inclusion of diverse botanical bioactives, suffer from non-standardized composition, and underexplore volatile antidiabetic constituents. Confronting these challenges, we developed Gluco Balance V (GB5), a cold-percolated ethanolic extract comprising equal proportions of bio-effective parts of Asparagus racemosus , Cyperus rotundus , Tinospora cordifolia , Terminalia arjuna , and Mimosa pudica . These botanicals were selected for complementary antidiabetic, antioxidant, and adiporegulatory activities documented in preclinical and clinical settings, indicating balanced, synergistic, and safe bioactivity. Methods: GB5’s phytochemical composition was standardized using gas chromatography–mass spectrometry (GC–MS) fingerprinting. In vitro assays assessed 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide (NO) scavenging capacity, inhibition of carbohydrate-digesting enzymes (α-amylase, α-glucosidase), enzyme kinetics, and effects on glucose uptake (GU) and lipid accumulation (LA) in yeast and 3T3-L1 adipocytes. Computational network pharmacology, molecular docking, and pharmacokinetic analyses elucidated molecular targets and bioavailability. Statistical analyses employed robust dose-response modelling, analysis of variance with Dunnett’s T3 test, and t-tests with false discovery rate correction. Results: GC–MS identified 21 bioactive compounds, including phytol, fatty acids, and sterols, driving GB5’s therapeutic synergy. GB5 showed robust antioxidant activity (DPPH and NO; half-maximal inhibitory concentration (IC 50 ) 88.6 and 74.8 µg/mL) and mixed-type inhibition of α-amylase and α-glucosidase (IC 50 71.6 and 174 µg/mL). At sub-inhibitory doses, it outperformed ascorbic acid (ASA) and acarbose. In 3T3-L1 adipocytes, GB5 increased GU by 32.3% at 2.0 mg/mL, comparable to rosiglitazone, and reduced lipid accumulation by 18.6% (90% effective concentration (EC 90 ) 0.742 mg/mL). Network pharmacology and molecular docking implicated peroxisome proliferator-activated receptor gamma (PPARγ), protein tyrosine phosphatase 1B (PTP1B), cyclooxygenase-2 (COX-2), and advanced glycation end-products–receptor for advanced glycation end-products (AGE–RAGE) pathways with 9,12-octadecadienoic acid and cholestan-3-ol, 2-methylene-, (3β,5α)- as key associates. Conclusions: GB5’s multi-targeted efficacy against hyperglycaemia, oxidative stress, and adipocyte dysfunction positions it as a promising complementary therapy for T2DM, meriting further in vivo evaluation. Graphical
- Open Access
- 3 April 2025
- Published by Universitas Nahdlatul Ulama Surabaya in Indonesian Journal of Medical Laboratory Science and Technology
- Vol. 7 (1) , 60-69
Quality assessment and biochemical characterization of probiotic Lactobacillus species isolated from yogurts fermented either by Tamarindus indica or Capsicum annuum
Yogurt is used to treat various digestive ailments. However, there are limited studies of the biochemical and microbiological properties of yogurt. This study aimed to assess the quality and biochemical characteristics of probiotic Lactobacillus species isolated from yogurts fermented with Tamarindus indica or Capsicum annuum. Three yogurt samples were used for analysis; two were homemade, using either Tamarindus indica L. or Capsicum annuum L. to initiate fermentation. Third was a commercial yogurt obtained from the grocery market. A proximate analysis was carried out. To identify microbiological strains, yogurt samples were cultured on nutrient- and De Man-Rogosa-Sharpe agars. Biochemical characteristics were examined, and probiotic species were identified through 16S rRNA analysis. The results showed that traditional yogurts had lower energy content due to reduced carbohydrate and fat levels while exhibiting higher protein content. Escherichia coli and coliforms were detected in the commercial yogurt, whereas traditional yogurts were free from these harmful bacteria, highlighting their potential safety. The biochemical characteristics of all yogurt samples were largely similar. C. annuum L. demonstrated a positive oxidase test, indicating the presence of an electron transport chain in the Lactobacillus species found in the yogurt fermented with C. annuum L. Microbial analysis revealed that L. acidophilus was predominant in traditional yogurt, while commercial yogurt contained L. plantarum. These findings suggest that homemade yogurts, with their higher protein content, lower fat and carbohydrate levels, and absence of harmful bacteria, offer a safer and potentially more beneficial probiotic alternative to commercial yogurt. The specific Lactobacillus strains present in traditional yogurts may contribute to their antimicrobial properties, supporting their probiotic potential.
- 3 April 2025
- Published by Universitas Nahdlatul Ulama Surabaya in Indonesian Journal of Medical Laboratory Science and Technology
- Vol. 7 (1) , 60-69
Open AccessQuality assessment and biochemical characterization of probiotic Lactobacillus species isolated from yogurts fermented either by Tamarindus indica or Capsicum annuum
Yogurt is used to treat various digestive ailments. However, there are limited studies of the biochemical and microbiological properties of yogurt. This study aimed to assess the quality and biochemical characteristics of probiotic Lactobacillus species isolated from yogurts fermented with Tamarindus indica or Capsicum annuum. Three yogurt samples were used for analysis; two were homemade, using either Tamarindus indica L. or Capsicum annuum L. to initiate fermentation. Third was a commercial yogurt obtained from the grocery market. A proximate analysis was carried out. To identify microbiological strains, yogurt samples were cultured on nutrient- and De Man-Rogosa-Sharpe agars. Biochemical characteristics were examined, and probiotic species were identified through 16S rRNA analysis. The results showed that traditional yogurts had lower energy content due to reduced carbohydrate and fat levels while exhibiting higher protein content. Escherichia coli and coliforms were detected in the commercial yogurt, whereas traditional yogurts were free from these harmful bacteria, highlighting their potential safety. The biochemical characteristics of all yogurt samples were largely similar. C. annuum L. demonstrated a positive oxidase test, indicating the presence of an electron transport chain in the Lactobacillus species found in the yogurt fermented with C. annuum L. Microbial analysis revealed that L. acidophilus was predominant in traditional yogurt, while commercial yogurt contained L. plantarum. These findings suggest that homemade yogurts, with their higher protein content, lower fat and carbohydrate levels, and absence of harmful bacteria, offer a safer and potentially more beneficial probiotic alternative to commercial yogurt. The specific Lactobacillus strains present in traditional yogurts may contribute to their antimicrobial properties, supporting their probiotic potential.